Table 1.

ER and PR status from different data sources among women ages 35 to 64 y with invasive breast cancer in the Women's CARE Study

Receptor status from a centralized pathology laboratoryReceptor status from SEER registries
ER statusER−ER+
    ER−316 (92%)122 (17%)
    ER+28 (8%)582 (83%)
    κ (95% CI)0.70 (0.65-0.74)
PR statusPR−PR+
    PR−296 (83%)121 (21%)
    PR+60 (17%)449 (79%)
    κ (95% CI)0.60 (0.55-0.65)
Joint ER/PR statusER−/PR−ER+/PR+ER+/PR−ER−/PR+
    ER−/PR−240 (90%)48 (9%)18 (20%)36 (69%)
    ER+/PR+8 (3%)392 (76%)38 (43%)8 (15%)
    ER+/PR−8 (3%)35 (7%)29 (33%)2 (4%)
    ER−/PR+10 (4%)38 (8%)3 (3%)6 (12%)
    Overall κ (95% CI)0.55 (0.51-0.59)
    ER−/PR− κ (95% CI)0.69 (0.64-0.74)
    ER+/PR+ κ (95% CI)0.62 (0.57-0.67)
    ER+/PR− κ (95% CI)0.30 (0.20-0.40)
    ER−/PR+ κ (95% CI)0.05 (−0.03 to 0.14)